Meeting
2022 ASCO Genitourinary Cancers Symposium
TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).
Authors
Scott T. Tagawa
Weill Cornell Medicine, New York, NY
Scott T. Tagawa , Petros Grivas , Daniel P. Petrylak , Cora N. Sternberg , Umang Swami , Astha Bhatia , Cabilia Pichardo , Trishna Goswami , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03547973
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS581)
DOI
10.1200/JCO.2022.40.6_suppl.TPS581
Abstract #
TPS581
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
TROPHU-U-01 cohort 5: Evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC).
First Author: Thomas Powles
Poster
2023 ASCO Genitourinary Cancers Symposium
TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC).
First Author: Ignacio Duran
Poster
2023 ASCO Annual Meeting
TROPHY-U-01 Cohort 4 (C4): Sacituzumab govitecan (SG) in combination with cisplatin (cis) as first-line (1L) therapy, followed by maintenance avelumab plus (+) SG or zimberelimab (zim) + SG in patients (pts) with treatment (Tx)-naïve metastatic urothelial cancer (mUC).
First Author: Chethan Ramamurthy
Poster
2023 ASCO Genitourinary Cancers Symposium
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
First Author: Philippe Barthelemy